Angioimmunoblastic T-Cell Lymphoma / Nodal TFH-cell lymphoma · line 1 · Brentuximab vedotin + CHP (BV-CHP), adult source-specific reference
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CHP-BV |
| ID | IND-AITL-1L-CHP-BV |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff |
| Diseases | DIS-AITL |
| Sources | SRC-ADCETRIS-US-LABEL SRC-ECHELON-2-FIVE-YEAR-2022 SRC-ESMO-EHA-PTCL-2025 |
Notes
Evidence wording corrected; regimen choice, safety assertions and regional authorization still require separate review. Clinical and language signoff pending.
Used By
Algorithms
ALGO-AITL-1L- ALGO-AITL-1L
Contraindications
CI-BRENTUXIMAB-BLEOMYCIN- CI-BRENTUXIMAB-BLEOMYCIN